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Abstract: Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor 
(DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other 
DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like 
peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is effective in lowering 
HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with 
other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and 
inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview 
of the mechanism of action, the pharmacology, and the clinical efﬁ  cacy and safety of sitagliptin 
in type 2 diabetes therapy.
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Utilizing the therapeutic potential of GLP-1 
in type 2 diabetes
Since glucagon-like peptide-1 (GLP-1) itself is not feasible for type 2 diabetes therapy 
due to its very short biological half-life, two major strategies have been developed to 
utilize the beneﬁ  cial effects of GLP-1 (Drucker 2006). On the one hand, long-acting, 
dipeptidyl-peptidase ihibitor (DPP-4 inhibitor)-resistant peptides with a high similarity 
to the native GLP-1 can be used as injectable therapeutic agents (incretin mimetics or 
GLP-1 analogues). Exendin-4, or exenatide in the recombinant form, is such a peptide 
originally found in the saliva of the gila monster. Exenatide has a very high amino 
acid sequence similarity with GLP-1 and is a GLP-1 receptor agonist. It has been 
approved for type 2 diabetes therapy for patients having insufﬁ  cient glucose control 
under a therapy with metformin, sulfonylureas, or a combination of both under the 
trade name Byetta® (Eli Lilly Pharmaceuticals, Indianapolis, IN, USA and Amylin 
Pharmaceuticals, San Diego, CA, USA) (Bray 2006). Liraglutide is a GLP-1 analogue 
under development by Novo Nordisk Pharmaceuticals (Copenhagen, Denmark) and is 
being evaluated for efﬁ  cacy and safety in type 2 diabetes in clinical studies in phase 
III (Feinglos et al 2005).
The other way to utilize GLP-1 effects in type 2 diabetes is the direct inhibition 
of DPP-4 by orally active substances (Deacon and Holst 2002). Sitagliptin (Januvia®, 
Merck Pharmaceuticals, Whitehouse Station NJ, USA) is a highly selective DPP-4 
inhibitor that has been approved for type 2 diabetes therapy. Other DPP-4 inhibitors 
are also in development or close to approval, such as vildagliptin (Galvus®, Novartis 
Pharmaceuticals, Basel, Switzerland).
DPP-4 inhibition in type 2 diabetes
The incretin effect is diminished in type 2 diabetes. Raising concentrations of intact 
GLP-1 can lower or even normalize plasma glucose in type 2 diabetic patients (Gallwitz Vascular Health and Risk Management 2007:3(2) 204
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2006). GLP-1 is degraded very rapidly by DPP-4, an enzyme 
that is localized vastly in the endothelium and can also be 
measured in the circulation. DPP-4 cleaves peptides with an 
N-terminal alanine or proline amino acid residue (Mentlein 
et al 1993). The two GLP-1 fragments resulting from DPP-4 
activity are both biologically inactive; the fragment GLP-1(9-36) 
amide has even been described as having GLP-1 antagonistic 
properties in some studies (Knudsen and Pridal 1996). DPP-4 
inhibition raises intact GLP-1 plasma concentrations to levels 
observed in the stimulated state after a meal. Besides GLP-1, 
which has a very high afﬁ  nity towards DPP-4 as a substrate, other 
peptides, such as glucose-dependent insulinotropic peptide (GIP), 
pituitary adenylate cyclase-activating polypeptide (PACAP), 
and gastrin-releasing peptide (GRP) (see Table 1) are also 
inactivated by DPP-4 by enzymatic cleavage. Some of these 
peptides also play a role in glucose homeostasis (Nauck and 
El-Ouaghlidi 2005). DPP-4 is also expressed on T-lymphocytes 
where it has also been described as CD-26 receptor. The effect 
of pharmacological inhibition of this receptor with DPP-4 
inhibitors has not been completely clariﬁ  ed yet, but so far, the 
DPP-4 inhibitors in development for the treatment of type 2 
diabetes have not shown any immunological adverse effects in 
this respect. Besides DPP-4, other dipeptidyl peptidases such 
as DPP-8 or DPP-9 also degrade peptide hormones. In the 
development of DPP-4 inhibitors it was important to have a high 
speciﬁ  city for DPP-4 and no inhibitory activity towards the other 
DPPs (Demuth et al 2005).
The pharmacological proﬁ  le 
of sitagliptin
Sitagliptin (MK-0431), chemically (2R)-4-Oxo-4-[3-
(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]-1-(2,4,5-triﬂ  uorophenyl)butan-2-amine (see Figure 
1) has a very high selectivity towards DPP-4, with an IC(50) of 
18 nM. There is no afﬁ  nity towards other DDP enzymes (DPP-
8 and DPP-9). It has been approved for the treatment of type 2 
diabetes in the USA and Europe and is registered by the name 
Januvia® (Merck Pharmaceuticals, Whitehouse Station, NJ, 
USA) (Kim et al 2005). In healthy volunteers and in patients with 
type 2 diabetes of different ethnic background, the tolerability 
of different doses given once or twice daily is good. The main 
pharmacokinetic parameters (Tmax, Cmax and t1/2) measured in 
studies were similar at baseline and in the steady state after longer 
administration. Steady-state plasma concentrations of sitaglitptin 
are reached after 3 days. Given once daily, the accumulation 
rate is modest (AUC accumulation ratio [day 10/day 1] range, 
1.05–1.29) (Bergman et al 2006; Miller and St Onge 2006). 
The elimination and excretion is mainly renal (75% of an oral 
dose is found in the urine as unchanged drug), and the rest is 
metabolized via the cytochromes CYP 3A4 and CYP 2C8. 
Drug–drug interactions were not observed under sitagliptin 
therapy in clinical studies, and especially no such interactions 
were found with other antihyperglyemic agents in type 2 diabetic 
patients (Herman et al 2006a). The elimination half-time is 12–14 
hours (Herman et al 2006b). Doses of 50–200 mg/d sitagliptin 
administered once daily lead to a ≥80% inhibition of DPP-4 over 
24 hours and sitagliptin plasma levels of >100 nM. As a result, the 
concentrations of biologically active, intact GLP-1 are increased 
2–3-fold in the postprandial state. In all the studies performed the 
safety data are very good and hypoglycemic episodes or other 
adverse events did not differ signiﬁ  cantly from those observed 
in the control groups. In monotherapy or in studies investigating 
a combination with metformin or thiazolidinediones (TZDs), 
sitagliptin did not cause hypoglycemia (Bergman et al 2006; 
Miller and St Onge 2006).
Animal studies with sitagliptin
Animal studies have been performed to investigate the 
effect of sitagliptin on beta- and alpha-cells in the pancreatic 
islets. Furthermore, the effect of sitagliptin on islet cell mass 
has been investigated. The latter studies were performed 
with des-ﬂ  uoro-sitagliptin in a rodent model with diabetes 
(high-fat-diet [HFD] treated, streptozotocin-induced [STZ] 
diabetic mice). The treatment with the sitagliptin analogue 
over a period of 2–3 months improved glycemic and lipid 
parameters in these mice (HbA1c, fasting and postprandial 
glucose, triglycerides, and free fatty acids). A histological 
evaluation of the islets in treated animals at the end of the 
study showed an increase in insulin-positive cells and a 
normalization of the beta- to alpha-cell ratio (see Figure 
Table 1 Hormones and regulatory peptides as substrates for 
DPP-4 (modiﬁ  ed according to Mentlein (1999)
With inﬂ  uence on   Without inﬂ  uence on 
activity and elimination  activity and elimination
GLP-1 GRH
GIP Interleukin  1β
GLP-2 Interleukin  2
PACAP   IGF-1
NPY Prolactin
PYY HCG
Substance Bradykinin
RANTES 
Abbreviations: DPP-4, dipeptidyl-peptidase inhibitor; GIP, gastric inhibitory poly-
peptide; GLP, glucagon-like peptide; GRH, gonadotrophin-releasing hormone; HCG, 
human chorionic gonatotrophin; IFG-1, insulin-like growth factor-1; 
NPY, neuropeptide Y; PACAP, pituitary adenylate cyclase-activating polypeptide; 
PYY, peptide YY; RANTES, regulated on activation, normal T cell expressed and 
secreted.Vascular Health and Risk Management 2007:3(2) 205
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2) (Mu et al 2006). The insulin secretion of isolated islets 
from sitagliptin-treated animals was signiﬁ  cantly higher than 
that of sulfonylurea-treated control animal islets, indicating 
that the effect was independent of ameliorating glucose 
toxicity. Sitagliptin might improve beta-cell function and 
beta-cell mass in type 2 diabetes according to these animal 
data (Mu et al 2006). In favor of this hypothesis are studies 
in isolated islets from mice treated with vildagliptin for 9 
weeks that show that glucose-stimulated insulin secretion 
was markedly enhanced (Ahren et al 2005). The beta-cell 
protective effect of DDP-4 inhibition is most likely GLP-1 
mediated. Incubation of INS-1 cells from an insulinoma cell 
line in vitro with GLP-1 show a dose-dependent inhibition 
of STZ-induced apoptosis of these cells. In animal studies 
in vivo, the administration of DPP-4 inhibitors signiﬁ  cantly 
increased endogenous GLP-1 concentrations along with the 
improvement in beta-cell function and mass (Pospisilik et 
al 2003). Other gut hormones like GIP, GRP, and PACAP 
might also contribute to this effect, as other animal studies 
including studies with a double receptor “knock-out” 
(DIRKO-mice) show. Further results in support come from 
mice deﬁ  cient in DPP-4/CD26 (CD26-/-; DPP-4-“knock-out” 
mice). These animals are resistant to STZ-induced diabetes 
and have elevated circulating plasma concentrations of intact 
GLP-1 and other incretin hormones (Marguet et al 2000). 
Nevertheless, further studies are needed to completely clarify 
the role of DPP-4 inhibitors on beta- and alpha-cell function 
and islet cell mass in type 2 diabetes.
Sitagliptin in clinical studies 
in type 2 diabetes
Sitagliptin improved the glycemic parameters HbA1c, fasting 
glucose, and postprandial glucose in clinical studies in patients 
with type 2 diabetes in monotherapy in doses of 100 mg and 
200 mg given once daily in a 24-week study. HbA1c was dose-
dependently reduced by 0.79% (100 mg/d) and 0.94% (200 
mg/d) as well as fasting glucose (17.1 mg/dL and 21.3 mg/dL, 
respectively) (Aschner et al 2006c). The postprandial glucose 
was signiﬁ  cantly reduced in a standardized meal-tolerance 
test (2 h postprandial glucose 46.7 mg/dL and 54.1 mg/dL, 
respectively). Beta-cell function as determined by HOMA-B, 
the postprandial insulin- and C-peptide responses, as well as 
the proinsulin/insulin ratio also improved in type 2 diabetic 
patients. In other monotherapy studies with durations of 12 
or 18 weeks, glycemic parameters were also improved in a 
comparable manner (Figure 4). In all monotherapy studies, 
sitagliptin was weight neutral, the 200 mg/d doses even led to a 
weight reduction of 1.1 kg in the study patients. While the 200 
mg dose was more potent than the 100 mg dose in the 24-week 
study by Ashner (Aschner et al 2006c), this slight difference 
in the potencies of 100 mg and 200 mg were not observed 
in the shorter 18-week study by Raz (Raz et al 2006c). This 
might be due to the differences in study durations as well as 
the different study populations. The maximal approved dose 
for sitagliptin is 100 mg daily. The sitagliptin therapy was well 
tolerated, and the incidence of hypoglycemia or other adverse 
events was not increased (Aschner et al 2006a, 2006b; Raz 
et al 2006a, 2006b).
In combination therapies as add on therapy to already 
existing oral antidiabetic treatment, the addition of sitagliptin 
(100 mg/d) to metformin led to a signiﬁ  cant reduction of 
HbA1c (0.65%), fasting plasma glucose (25.4 mg/dL), and 
postprandial glucose (2 h) (50.6 mg/dL) after 24 weeks. The 
baseline HbA1c in this study was 8.0%. As in the monotherapy 
studies, beta-cell function measured by the above parameters 
improved. The addition of sitagliptin to the ongoing metformin 
therapy was also weight neutral, the combination therapy was 
well tolerated and the gastrointestinal side-effects as well as 
hypoglycemic episodes were not increased (Charbonnel et al 
2006; Karasik et al 2006).
Comparable results were observed in a study with similar 
design with an add-on combination of sitagliptin to an existing 
pioglitazone therapy. As in the metformin combination 
study, the glycemic parameters HbA1c, and fasting and 2-h 
postprandial glucose improved. From a baseline HbA1c of 
7.9%, a signiﬁ  cantly higher percentage of patients reached 
a target HbA1c <7.0% (45%) compared with the group 
continuing on pioglitazone monotherapy (23%). Sitagliptin was 
again weight neutral for the development of the body weight in 
the patients with pioglitazone treatment. The incidence of side-
effects was similar in the combination therapy and pioglitazone 
monotherapy groups, the incidence of hypoglycemias was not 
Figure 1 Structural formula of sitagliptin.Vascular Health and Risk Management 2007:3(2) 206
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Figure 2 Morphometric analysis of islet cell composition in STZ-induced diabetic mice after MK0431 (des-ﬂ  uoro-sitagliptin) treatment. Digital images of immunohisto-
chemically stained pancreas sections were captured to quantify the percentage of insulin-positive area in whole pancreas sections as beta-cell volume (A) (#p < 0.03 vs 
vehicle-treated group; n = 4 animals), and ratios of insulin positive beta-cell to total islet area (B).*p < 0.001 vs vehicle-treated group. Reproduced with permission from 
Mu J, Woods J, Zhou YP, et al. 2006. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model 
of type 2 diabetes. Diabetes, 55:1695-704. Copyright © 2006 The American Diabetes Association.
Abbreviations: STZ, streptozotocin-induced.Vascular Health and Risk Management 2007:3(2) 207
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higher with the combination of sitagliptin and pioglitazone 
(Rosenstock et al 2006a, 2006b).
In two studies investigating sitagliptin monotherapy and 
one study investigating the combination of sitagliptin with 
metformin, beta-cell function was estimated using a frequent-
sampling meal-tolerance test in a subgroup of patients. In 
these studies basal and stimulated insulin responses were 
improved as well as the disposition index. The sensitivity of 
the beta-cells to glucose was enhanced, whereas the incidence 
of hypoglycemic episodes remained very low, suggesting a 
glucose-dependent mechanism for beta-cell responsiveness 
(Xu et al 2006a, 2006b).
Sitagliptin was also generally well tolerated and effective 
in patients with impaired renal function. In this study, a dose 
of 25 mg/d was chosen for patients with a creatinine clearance 
of <30 mL/min or end stage renal disease, and a dose of 
50 mg/d was given to patients with a creatinine clearance 
between 30 and 50 mL/min (Scott et al 2006).
Perspectives
Sitagliptin has been shown to be effective, well tolerated, 
and safe in the treatment of type 2 diabetes in monotherapy 
or in the combination with metformin or thiazolidinediones. 
It reduces the glycemic parameters HbA1c, and fasting and 
postprandial glucose and improves beta-cell function. The 
reduction of HbA1c observed in the studies was at least as 
good as that seen with other oral antihyperglycemic agents. 
In this respect, it has to be noted, however, that the potency 
of HbA1c reduction in type 2 diabetes by oral agents is also 
dependent on the baseline HbA1c; in studies with higher 
baseline HbA1c values, usually higher reductions of HbA1c 
are observed.
Sitagliptin is weight neutral and does not increase the 
incidence of hypoglycemic episodes or the occurrence of 
adverse events. The studies published so far contain data 
from up to 24 weeks; longer studies will be published soon. 
In man, long-term data on immunological effects mediated 
by CD-26 are unknown yet, but to date, no alterations in 
immune functions have been detected in clinical studies or 
long-term animal studies.
Sitagliptin and DPP-4 inhibitors in general address a 
novel multimodal principle of action in type 2 diabetes. By 
preserving stimulated circulating plasma levels of incretin 
hormones, insulin secretion is stimulated under hyperglycemic 
conditions and glucagon secretion is suppressed. Therefore, 
not only insulin secretion and insulin resistance are altered, 
as by the previously used oral antihyperglycemic agents, 
but also unmet needs of type 2 diabetes therapy are covered 
by this novel therapeutic principle (Ahren 2005; Gallwitz 
2006).
Figure 3 Fasting plasma glucose (FPG, left panel) and postprandial glucose (PPG, right panel) in sitagliptin (100 mg/d) monotherapy over 24 weeks in formerly drug-naïve 
patients with type 2 diabetes. From data of Aschner et al (2006a). Vascular Health and Risk Management 2007:3(2) 208
Gallwitz
Figure 4 Mean (±SEM) HbA1c (a) and fasting plasma glucose (b) over time for placebo (open circles), once-daily sitagliptin 100 mg (solid diamonds) and once-daily 
sitagliptin 200 mg (solid squares) groups. Reproduced with permission from Raz I, Hanefeld M, Xu L, et al.  2006c. Efﬁ  cacy and safety of the dipeptidyl peptidase-4 inhibitor 
sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia, 49:2564–71. Copyright © 2006 Springer Science and Business Media.
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Figure 5 HbA1c development in combination therapies of sitagliptin as add on to either metformin or pioglitazone. The results of the combination studies on HbA1c 
development are shown for the 24-week study with metformin (left panel) (from data of Karasik et al 2006) and for the study with pioglitazone (right panel) (from data of 
Rosenstock et al 2006a).
Abbreviations: Pbo, placebo.
Figure 6 Percentage of patients reaching the HbA1c goal of <7% in mono or combination therapy studies with sitagliptin. Studies of 24 weeks’ duration are shown: 
sitagliptin monotherapy (left panel) (from data of Aschner et al 2006b), combination with metformin (middle panel) (from data of Karasik et al 2006), combination with 
pioglitazone (right panel) (from data of Rosenstock et al 2006a).Vascular Health and Risk Management 2007:3(2) 210
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In case the effects observed on beta-cell function and 
beta-cell mass in preclinical studies also apply to human 
studies, sitagliptin could also have the potential to be 
useful in pre-diabetic stages and early stages of type 
2 diabetes to retard or prevent the disease progression 
(Gallwitz 2006).
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